schizophrenia. schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: Patients receive 40 mg buspirone and the second generation antipsychotic equivalent of 2-6 mg of risperidon. Intervention 2: Control group: patients with schizoph
Treatment - Drugs
Placebo
Intervention group: Patients receive 40 mg buspirone and the second generation antipsychotic equivalent of 2-6 mg of risperidon.
Control group: patients with schizophrenia receive 40mg placebo with the second generation of 2-6 mg of risperidone. Placebo pill will be like buspirone about the shape, color, smell and size.
Sponsors
Vice chancellor for research Ahvaz Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Age between 18 and 65 years old; Having schizophrenia according to DSM-VI-TR criteria; Bold negative symptoms( PANSS negative symptom sub-scale score more than 15); Disease duration of more than six months Exclusion criteria: Bipolar disorders; Depression and other psychiatric disorders; Chronic medical conditions (liver, kidney and heart); A history of sensitivity to antipsychotics or buspirone; A history of failure to respond to treatment with adequate doses of antipsychotic medication; History of seizures; Pregnancy; Breastfeeding; Any disruption in the electrocardiogram; Simultaneous treatment with other drugs and active suicidal thoughts
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative symptoms. Timepoint: Before intervention, Three and six weeks after intervention. Method of measurement: PANSS questioner. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHatam Boostani
Ahvaz Jundishapur University of Medical Sciences
Outcome results
None listed